Skip to main content

Insulet Corporation (PODD)

NASDAQ Stock Market Healthcare Medical - Devices
53.0Fair

ValueMarkers Composite Index

Top 47%#24,040 of 45,191

DCF data not available

Piotroski
7/9
Strong
Beneish
-2.12
Investigate
Altman
7.17
Safe
DCF Value
-
N/A
ROIC
13.6%
Adequate
P/E
58.2
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

CEO: Ashley A. McEvoy3,900 employeesUSwww.insulet.com

Deep Dive Analysis

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.